Aurobindo hits 2-year low; dips 11% in a week on USFDA's 6 observations 0 17.05.2022 10:12 Business Standard Analysts at ICICI Securities expect Aurobindo Pharma's adjusted PAT to de-grow 30.4 per cent year-on-year (YoY) to Rs 557.90 crore in the March 2022 quarter. Партнёры Smi24.net Все новости за 24 часа Музыкальные новости Агрегатор новостей 24СМИ
